Replies to post #76309 on Anavex Life Sciences Corp (AVXL)

[Doktornolittle]

That this presentation just restated those results is pretty reasonable. It did so to people not following AVXL. People not like us.

I am not great at critiquing clinical or mouse data, but the original PR sounded pretty good to me. A pre-clinical is not a great measure, but it is a measure, and these results sounded fantastic.

And the results came from a Swedish Stewardess. Everyone knows that Australian men from the outback and Swedish Stewardesses can be trusted.

And it is not the meat it's... the notion. Everyone knows that. The notion here is that Anavex 273 could really help some people. MJF included. The question is whether the results will be looked at for the near term grants... I think they will, but I do not know anything more than anyone else here... and if George says too late for this round... well George is always positive... so... maybe not this round.

I have some major reservations about AVXL, but much is alleviated knowing that Parkinsons has at least one major subclass that is an orphan candidate. A very large subclass that is just barely small enough to be orphan. Alzheimer's also has such subclasses.

I have not been looking at AVXL recently until these preclinical results. I think they are exciting. I am excited for MJF and MJFF and all the Parkinsons patients around the world.